Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 1053–1054 (1 October 2008) | doi:10.1038/nbt1008-1053
CD20 blockers eye crowded rheumatology market
Abstract
When trial results for a novel cancer drug were trumpeted in July, the rheumatology field felt the ripples. The drug is ofatumumab, a monoclonal antibody (mAb) targeting the CD20 molecule on B lymphocytes.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
